CRADLE-5:阶梯楔形2型混合实施-效果整群随机对照试验,评估CRADLE生命体征预警干预在塞拉利昂常规产科护理中真实世界推广
CRADLE-5为阶梯楔形整群随机对照试验,在塞拉利昂八个农村地区评估CRADLE生命体征预警干预对比常规产科护理,每六周一个地区从对照转为干预,为期1年(2022年5月至2023年6月)。主要结局为孕产妇死亡、死产、子痫和急诊子宫切除的复合率,同时进行混合方法过程与推广评价及成本效果分析。
要点
- CRADLE干预包含可准确测量血压和脉搏并内置交通灯预警系统的设备及针对性培训包。
- 试验在塞拉利昂八个农村地区开展,每六周一个地区从对照转为干预,为期1年。
- 主要结局为孕产妇死亡、死产、子痫和急诊子宫切除的复合率。
核心结论
- 该试验将探究CRADLE干预的国家级推广能否降低孕产妇和胎儿死亡及严重孕产妇不良结局,并了解在低资源环境中采用、整合和可持续性的策略。
- 若成功,目标是制定可适应、基于证据的推广路线图以改善母婴结局。
研究设计与样本
- CRADLE-5为阶梯楔形整群随机对照试验,比较CRADLE干预与常规产科护理,覆盖塞拉利昂八个农村地区(邦特、法拉巴、卡雷内、凯拉洪、科伊纳杜古、科诺、莫扬巴、通科利利)。
- 每个地区在1年内(2022年5月至2023年6月)以六周间隔从对照转为干预。
- 纳入在所在地区寻求产科护理的所有被识别为妊娠或产后六周内的女性。
- 采用混合方法过程和推广评价(依据医学研究理事会复杂干预指南和世界卫生组织ExpandNet工具),探索保真度、采纳、适应等实施结局以及覆盖、维持、可持续性和整合等推广结局。
- 同时进行成本效果分析。
主要发现
- CRADLE生命体征预警干预(一种可准确、易使用、测量血压和脉搏并内置交通灯预警系统的设备及针对性培训包)在塞拉利昂城市地区试验时与子痫和孕产妇死亡率降低相关。
- 随后实施试点成功,体现在保真度、可行性和采纳等指标上。
关键数值与推荐
- 主要结局数据为孕产妇死亡、死产、子痫和急诊子宫切除的复合率。
临床怎么用
- 国际指南推荐所有妊娠和产后女性定期进行血压评估,且医护人员应接受充分培训以应对异常。
- CRADLE干预在更农村地区改善母婴健康的临床有效性及其大规模整合和可持续性的难易程度尚待研究。
局限性
- CRADLE干预在更农村地区改善母婴健康的临床有效性尚待研究。
- CRADLE干预大规模整合和可持续性的难易程度尚待研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CRADLE Vital Signs Alert intervention (an accurate easy-to-use device that measures blood pressure and pulse with inbuilt traffic-light early warning system, and focused training package) was associated with reduced rates of eclampsia and maternal death when trialled in urban areas in Sierra Leone. Subsequently, implementation was successfully piloted as evidenced by measures of fidelity, feasibility and adoption. The CRADLE-5 trial will examine whether national scale-up, including in the most rural areas, will reduce a composite outcome of maternal and fetal mortality and maternal morbidity and will evaluate how the CRADLE package can be embedded sustainably into routine clinical pathways. METHODS: CRADLE-5 is a stepped-wedge cluster-randomised controlled trial of the CRADLE intervention compared to routine maternity care across eight rural districts in Sierra Leone (Bonthe, Falaba, Karene, Kailahun, Koinadugu, Kono, Moyamba, Tonkolili). Each district will cross from control to intervention at six-weekly intervals over the course of 1 year (May 2022 to June 2023). All women identified as pregnant or within six-weeks postpartum presenting for maternity care in the district are included. Primary outcome data (composite rate of maternal death, stillbirth, eclampsia and emergency hysterectomy) will be collected. A mixed-methods process and scale-up evaluation (informed by Medical Research Council guidance for complex interventions and the World Health Organization ExpandNet tools) will explore implementation outcomes of fidelity, adoption, adaptation and scale-up outcomes of reach, maintenance, sustainability and integration. Mechanisms of change and contextual factors (barriers and facilitators) will be assessed. A concurrent cost-effectiveness analysis will be undertaken. DISCUSSION: International guidance recommends that all pregnant and postpartum women have regular blood pressure assessment, and healthcare staff are adequately trained to respond to abnormalities. Clinical effectiveness to improve maternal and perinatal health in more rural areas, and ease of integration and sustainability of the CRADLE intervention at scale has yet to be investigated. This trial will explore whether national scale-up of the CRADLE intervention reduces maternal and fetal mortality and severe maternal adverse outcomes and understand the strategies for adoption, integration and sustainability in low-resource settings. If successful, the aim is to develop an adaptable, evidence-based scale-up roadmap to improve maternal and infant outcomes. TRIAL REGISTRATION: ISRCTN 94429427. Registered on 20 April 2022.
引用
- Ridout AE, Moses FL, Herm-Singh S, et al. CRADLE-5: a stepped-wedge type 2 hybrid implementation-effectiveness cluster randomised controlled trial to evaluate the real-world scale-up of the CRADLE Vital Signs Alert intervention into routine maternity care in Sierra Leone-study protocol. Trials. 2023. PMID: 37723530. doi:10.1186/s13063-023-07587-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。